Cover Image
市場調查報告書

Duodopa(帕金森氏症)- 預測與市場分析

Duodopa (Parkinson's Disease) - Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 301430
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
Back to Top
Duodopa(帕金森氏症)- 預測與市場分析 Duodopa (Parkinson's Disease) - Forecast and Market Analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 59 Pages
簡介

帕金森氏症的症狀是以動作緩慢、肌肉僵硬、震顫和姿勢不穩為特徵的一個漸進式疾病。是發病率第二高的神經退化性疾病,無論何種年齡層都有受到影響的可能性,得病率隨著年齡增長而上升,高齡者更是常見。雖然多巴胺療法對動作遲緩相當有效,但仍留有許多未滿足需求。

本報告提供帕金森氏症治療藥物──Duodopa之調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預測
    • QOL
  • 症狀

第4章 疾病的管理

  • 概要
  • 治療概要
  • 帕金森氏症的評估規模

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 左旋多巴混合製劑

第6章 Duodopa(carbidopa/levodopa intestinal gel)

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 預測

第7章 附錄

圖表

目錄
Product Code: GDHC391DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Developed by AbbVie, Duodopa is a gel composed of carbidopa/levodopa and administered via a pump into the intestine, where the drug is absorbed. It is approved for patients with advanced Parkinson's disease with motor fluctuations. Continual infusion provides steady state serum drug levels, while the patient experiences relative freedom from oral medications and optimal control of motor symptoms, including ON-OFF and dyskinesias.

Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Duodopa including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Duodopa for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Duodopa performance
  • Obtain sales forecast for Duodopa from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's Disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Levodopa Combination Therapy

6. Duodopa (carbidopa/levodopa intestinal gel)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Parkinson's Disease Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Compliance Assumptions
    • 7.4.5. Individual Drug Assumptions
    • 7.4.6. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Author
    • 7.6.2. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 9: Leading Treatments for Parkinson's Disease, 2014
  • Table 10: Product Profile - Duodopa
  • Table 11: Duodopa SWOT Analysis, 2014
  • Table 12: Global Sales Forecasts ($m) for Duodopa, 2012-2022

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
Back to Top